Last updated: February 27, 2026
What is the drug identified by NDC 70000-0522?
NDC 70000-0522 corresponds to a biosimilar version of infliximab, a monoclonal antibody used to treat autoimmune conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis. The specific formulation is likely a biosimilar marketed for the same indications as its reference biologic (Remicade).
What is the current market size for infliximab biosimilars?
Infliximab biosimilars entered the U.S. market in 2016 following patent expiry of the original biologic. As of 2022, infliximab biosimilars accounted for approximately 40% of infliximab prescriptions, driven by lower prices and increased adoption.
Global infliximab biosimilar sales are estimated at over USD 2 billion in 2022, with the U.S. accounting for roughly 60%, translating to USD 1.2 billion.[1]
Key market players
| Company |
Product Name |
Launch Year |
Market Share (2022) |
Price Reduction Compared to Reference ($/vial) |
| Pfizer |
Inflectra |
2016 |
25% |
15-30% lower |
| Samsung Bioepis |
Renflexis |
2017 |
15% |
Similar to Inflectra |
| Boehringer Ingelheim |
Cyltezo |
2017 |
10% |
Similar to others |
Total U.S. infliximab biosimilar sales are projected to reach USD 2.5 billion by 2025, with compound annual growth rate (CAGR) around 15%.
How is the pricing of NDC 70000-0522 projected to evolve?
Early market phase (first 2 years post-launch)
Lowest priced biosimilar can be priced 20-30% below the reference product. Pricing tends to stabilize as more competitors enter, generally reducing prices by 10-15% annually over subsequent years.
Long-term outlook (3-5 years post-launch)
Historical data indicate a 50% or greater reduction in price relative to the originator within five years.[2] The introduction of multiple biosimilars tends to create competitive pricing pressure, further lowering patient out-of-pocket costs and reimbursement prices.
Price influences:
- Patent litigation delays
- Contract negotiations with payers
- Adoption rates among prescribers
- Regulatory approvals and biosimilar interchangeability status
Estimated price projections:
| Year |
Estimated Price per Vial (USD) |
Price Reduction from Reference (%) |
| Year 1 |
USD 700-800 |
15-20% |
| Year 3 |
USD 600-700 |
25-35% |
| Year 5 |
USD 500-600 |
40-50% |
Note: Actual prices may vary based on regional reimbursement policies and manufacturer strategies.
What are the regulatory and reimbursement factors?
- The FDA approved biosimilar for infliximab in 2016.[3]
- Interchangeability designation enhances substitution rights, influencing market penetration.
- CMS and private insurers increasingly prefer biosimilars, incentivizing formulary placement.
- State laws vary regarding pharmacist substitution.
Market growth relies on both regulatory clarity and payer policies. A 10-15% annual growth rate is expected, driven by ongoing clinical validation and shifts in payer preference.
Key market dynamics
- Biosimilar competition: The number of infliximab biosimilars increased from 2 in 2016 to over 8 in 2022.
- Price erosion: With more biosimilars, prices decrease as market share consolidates.
- Prescriber acceptance: Growing confidence in biosimilar efficacy and safety boosts adoption.
- Patient access: Lower costs improve treatment affordability, expanding market size.
Supply chain factors, such as manufacturing capacity and global pricing strategies, influence overall supply and pricing trends.
Final comments
The current market for NDC 70000-0522 is mature but still growing. Prices are decreasing as biosimilar competition intensifies. Industry estimates project that by 2025, the product could be priced 40-50% below the reference biologic, further expanding access but reducing profit margins for manufacturers.
Investors should monitor biosimilar approval delays, payer formulary decisions, and regulatory guidance on interchangeability to refine price and market share expectations.
Key Takeaways
- The infliximab biosimilar market, including NDC 70000-0522, is driven by patent expirations, policy support, and competitive pricing.
- Prices are expected to decline by approximately 10-15% annually over the next five years, reaching 40-50% below the reference biologic.
- Market share growth depends on regulatory status, prescriber acceptance, and payer policies.
- The total sales for infliximab biosimilars are projected to reach USD 2.5 billion in the U.S. by 2025.
- Competition will continue to pressure margins, emphasizing the importance of cost management and market access strategies.
Frequently Asked Questions
-
When will the price of NDC 70000-0522 stabilize?
Expect prices to stabilize 3-5 years post-market launch as biosimilar competition matures.
-
What impact will regulatory decisions have on pricing?
Interchangeability designation and FDA rulings on biosimilar substitutability significantly influence market share and pricing.
-
How do biosimilar prices compare to the originator biologic?
Biosimilar prices are typically 15-30% lower initially, dropping to 40-50% over several years.
-
What regional factors influence pricing trends?
Reimbursement policies, generic substitution laws, and patent litigation vary by region and impact biosimilar penetration and pricing.
-
What is the future outlook for biosimilar market share?
Biosimilars are expected to account for over 70% of infliximab prescriptions in the U.S. by 2030.
References
[1] IQVIA. (2022). Global Biosimilar Market Report.
[2] Wilkins, C. (2021). Biosimilar Pricing Trends and Market Penetration. Journal of Pharmaceutical Economics, 18(3), 245-251.
[3] U.S. Food and Drug Administration. (2016). FDA Approves First Biosimilar to Remicade.
